A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Stefan Cordes,Morie A. Gertz,Francis K. Buadi,Yi Lin,Martha Q. Lacy,Prashant Kapoor,Shaji Kumar,Arleigh McCurdy,Angela Dispenzieri,David Dingli,Suzanne R. Hayman,William J. Hogan,Rajiv K. Pruthi +12 more
TL;DR: The decision to offer autologous stem cell transplant (ASCT) to factor X-deficient patients as both appropriate and efficacious is supported.
Journal ArticleDOI
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.
Abdullah S. Al Saleh,Abdullah S. Al Saleh,M. Hasib Sidiqi,Angela Dispenzieri,Prashant Kapoor,Eli Muchtar,Francis K. Buadi,Rahma Warsame,Martha Q. Lacy,David Dingli,Nelson Leung,Wilson I. Gonsalves,Taxiarchis Kourelis,Morie A. Gertz,Ronald S. Go,Robert A. Kyle,S. Vincent Rajkumar,Shaji Kumar +17 more
TL;DR: A hematopoietic score can predict survival in newly diagnosed myeloma patients and Predictors of OS on the multivariable analysis were age, age (HR, 1.93; P < .0001), R‐ISS stage (1‐2 vs 3) ( HR, 0.48; P< ).
Journal ArticleDOI
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
Mark R. Litzow,Prema P. Peethambaram,Stephanie L. Safgren,Gary L. Keeney,S. M. Ansell,Angela Dispenzieri,Michelle A. Elliott,Dennis A. Gastineau,Morie A. Gertz,David J. Inwards,Martha Q. Lacy,Ivana N. Micallef,Luis F. Porrata,Wilma L. Lingle,Lynn C. Hartmann,Marlene H. Frost,Brigitte A. Barrette,Harry J. Long,Vera J. Suman,Joel M. Reid,Matthew M. Ames,Scott H. Kaufmann +21 more
TL;DR: Topotecan can safely be dose escalated to 4.5 mg/m2/d in combination with CY, carboplatin and AHSCT for the treatment of relapsed or persistent platinum sensitive ovarian or primary peritoneal carcinoma.
Journal ArticleDOI
Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cell Neoplasms
Alla Keyzner,Anita D'Souza,Martha Q. Lacy,Morie A. Gertz,Suzanne R. Hayman,Francis K. Buadi,Shaji Kumar,David Dingli,Ann Engebretson,Caili Tong,Angela Dispenzieri +10 more
TL;DR: Differences in the peri-transplantation cytokine milieu may explain the higher transplantation morbidity in patients with POEMS syndrome, a rare, multisystem, plasma cell neoplasm.
Journal ArticleDOI
In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)
Paolo Milani,Paolo Milani,Angela Dispenzieri,Morie A. Gertz,Martha Q. Lacy,Francis K. Baudi,Shaji Kumar,Mathew S. Maurer,Kyle W. Klarich,Suzanne R. Hayman,Nelson Leung,David Dingli,John A. Lust,Yi Lin,Prashant Kapoor,Ronald S. Go,Yi L. Hwa,Steven R. Zeldenrust,Robert A. Kyle,S. Vincent Rajkumar,Martha Grogan +20 more
TL;DR: The goal was to assess the prognostic role of MCF in a large cohort of patients with AL amyloidosis in the context of other prognostic variables, and it was independent of the Mayo (2012) staging but highly correlated with LV strain.